NO322653B1 - Fremgangsmate for femstilling av et in vitro peptid- eller proteinekspresjonsbibliotek, peptid- eller proteinekspresjonsbibliotek, fremgangsmate for a identifisere et malmolekyl, samt bifunksjonell molekylaer probe for anvendelse i en slik fremgangsmate. - Google Patents
Fremgangsmate for femstilling av et in vitro peptid- eller proteinekspresjonsbibliotek, peptid- eller proteinekspresjonsbibliotek, fremgangsmate for a identifisere et malmolekyl, samt bifunksjonell molekylaer probe for anvendelse i en slik fremgangsmate. Download PDFInfo
- Publication number
- NO322653B1 NO322653B1 NO19993953A NO993953A NO322653B1 NO 322653 B1 NO322653 B1 NO 322653B1 NO 19993953 A NO19993953 A NO 19993953A NO 993953 A NO993953 A NO 993953A NO 322653 B1 NO322653 B1 NO 322653B1
- Authority
- NO
- Norway
- Prior art keywords
- dna
- protein
- library
- binding
- peptide
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 317
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 288
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 178
- 238000000034 method Methods 0.000 title claims abstract description 78
- 230000014509 gene expression Effects 0.000 title claims abstract description 61
- 238000000338 in vitro Methods 0.000 title claims description 57
- 230000001588 bifunctional effect Effects 0.000 title claims description 15
- 239000000523 sample Substances 0.000 title claims description 15
- 108010067902 Peptide Library Proteins 0.000 title description 8
- 108020004414 DNA Proteins 0.000 claims abstract description 172
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 55
- 239000002773 nucleotide Substances 0.000 claims abstract description 22
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 16
- 230000027455 binding Effects 0.000 claims description 119
- 238000009739 binding Methods 0.000 claims description 118
- 238000013519 translation Methods 0.000 claims description 55
- 239000012634 fragment Substances 0.000 claims description 42
- 230000004568 DNA-binding Effects 0.000 claims description 35
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 27
- 102000053602 DNA Human genes 0.000 claims description 24
- 108091026890 Coding region Proteins 0.000 claims description 23
- 239000003550 marker Substances 0.000 claims description 23
- 230000002068 genetic effect Effects 0.000 claims description 17
- 238000003556 assay Methods 0.000 claims description 11
- 239000013598 vector Substances 0.000 claims description 11
- 238000001514 detection method Methods 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 108091034117 Oligonucleotide Proteins 0.000 claims description 5
- 125000000539 amino acid group Chemical group 0.000 claims description 5
- 239000003068 molecular probe Substances 0.000 claims description 5
- 238000010367 cloning Methods 0.000 claims description 4
- 241000702192 Escherichia virus P2 Species 0.000 claims description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 238000010276 construction Methods 0.000 abstract description 10
- 238000012163 sequencing technique Methods 0.000 abstract description 5
- 238000012216 screening Methods 0.000 abstract description 2
- 239000003446 ligand Substances 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 204
- 230000014616 translation Effects 0.000 description 54
- 238000003752 polymerase chain reaction Methods 0.000 description 40
- 239000013612 plasmid Substances 0.000 description 38
- 239000000463 material Substances 0.000 description 37
- 230000003321 amplification Effects 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 33
- 238000003199 nucleic acid amplification method Methods 0.000 description 33
- 238000001727 in vivo Methods 0.000 description 31
- 239000013077 target material Substances 0.000 description 30
- 238000013518 transcription Methods 0.000 description 28
- 230000035897 transcription Effects 0.000 description 28
- 150000007523 nucleic acids Chemical class 0.000 description 25
- 239000000284 extract Substances 0.000 description 23
- 102000039446 nucleic acids Human genes 0.000 description 22
- 108020004707 nucleic acids Proteins 0.000 description 22
- 101800001494 Protease 2A Proteins 0.000 description 20
- 101800001066 Protein 2A Proteins 0.000 description 20
- 230000010076 replication Effects 0.000 description 20
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 19
- 235000001014 amino acid Nutrition 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 102000004190 Enzymes Human genes 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 15
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 14
- 102000037865 fusion proteins Human genes 0.000 description 14
- 108020001507 fusion proteins Proteins 0.000 description 14
- 101710096438 DNA-binding protein Proteins 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 108090001008 Avidin Proteins 0.000 description 12
- 230000001939 inductive effect Effects 0.000 description 12
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 12
- 239000000872 buffer Substances 0.000 description 11
- 238000003776 cleavage reaction Methods 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 11
- 230000007017 scission Effects 0.000 description 11
- 230000009466 transformation Effects 0.000 description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 9
- 238000002955 isolation Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 102000014914 Carrier Proteins Human genes 0.000 description 8
- 108091033380 Coding strand Proteins 0.000 description 8
- 108091008324 binding proteins Proteins 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 8
- 238000010828 elution Methods 0.000 description 8
- 230000002255 enzymatic effect Effects 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 7
- 230000003115 biocidal effect Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 229960002685 biotin Drugs 0.000 description 7
- 239000011616 biotin Substances 0.000 description 7
- 230000001747 exhibiting effect Effects 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 6
- 108091081024 Start codon Proteins 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000005755 formation reaction Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 235000020958 biotin Nutrition 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 241001515965 unidentified phage Species 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 108010090804 Streptavidin Proteins 0.000 description 4
- 229920004890 Triton X-100 Polymers 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 210000003705 ribosome Anatomy 0.000 description 4
- 238000010187 selection method Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 108020004638 Circular DNA Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- 108010022407 arginyl-leucyl-cysteinyl-arginyl-isoleucyl-valyl-valyl-isoleucyl-arginyl-valyl-cysteinyl-arginyl-seryl-aspartyl-aspartyl-aspartyl-glutamyl-glutamic acid (3-11)disulfide Proteins 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000005734 heterodimerization reaction Methods 0.000 description 3
- 235000014304 histidine Nutrition 0.000 description 3
- 125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 210000002729 polyribosome Anatomy 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 108010000633 signal peptide receptor Proteins 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102100039556 Galectin-4 Human genes 0.000 description 2
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 2
- 101710192606 Latent membrane protein 2 Proteins 0.000 description 2
- 101710150114 Protein rep Proteins 0.000 description 2
- 101710152114 Replication protein Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- 101710109576 Terminal protein Proteins 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- -1 for example Chemical class 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 238000002708 random mutagenesis Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000010396 two-hybrid screening Methods 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IDOQDZANRZQBTP-UHFFFAOYSA-N 2-[2-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1OCCO IDOQDZANRZQBTP-UHFFFAOYSA-N 0.000 description 1
- 108091092742 A-DNA Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 108010075613 DNA replicase Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 101000889812 Enterobacteria phage T4 Endonuclease Proteins 0.000 description 1
- 241000701867 Enterobacteria phage T7 Species 0.000 description 1
- 241000702374 Enterobacteria phage fd Species 0.000 description 1
- 241001147440 Escherichia virus 186 Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 241000288105 Grus Species 0.000 description 1
- 101150031823 HSP70 gene Proteins 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 108091060545 Nonsense suppressor Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000006010 Protein Disulfide-Isomerase Human genes 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 101100465903 Schizosaccharomyces pombe (strain 972 / ATCC 24843) psp3 gene Proteins 0.000 description 1
- 102100026900 Signal recognition particle receptor subunit alpha Human genes 0.000 description 1
- 101710126382 Signal recognition particle receptor subunit alpha Proteins 0.000 description 1
- 101710111458 Signal recognition particle receptor subunit alpha homolog Proteins 0.000 description 1
- 102100026904 Signal recognition particle receptor subunit beta Human genes 0.000 description 1
- 101710102726 Signal recognition particle receptor subunit beta Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 108010001244 Tli polymerase Proteins 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 229920004929 Triton X-114 Polymers 0.000 description 1
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 1
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 102000012086 alpha-L-Fucosidase Human genes 0.000 description 1
- 108010061314 alpha-L-Fucosidase Proteins 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000009831 antigen interaction Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 1
- 230000035071 co-translational protein modification Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 101150052825 dnaK gene Proteins 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108020003519 protein disulfide isomerase Proteins 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000012205 qualitative assay Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical class [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1075—Isolating an individual clone by screening libraries by coupling phenotype to genotype, not provided for in other groups of this subclass
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10111—Myoviridae
- C12N2795/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Glass Compositions (AREA)
- Iron Core Of Rotating Electric Machines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9703369.0A GB9703369D0 (en) | 1997-02-18 | 1997-02-18 | Process |
| PCT/GB1998/000518 WO1998037186A1 (en) | 1997-02-18 | 1998-02-18 | In vitro peptide or protein expression library |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO993953D0 NO993953D0 (no) | 1999-08-17 |
| NO993953L NO993953L (no) | 1999-10-18 |
| NO322653B1 true NO322653B1 (no) | 2006-11-13 |
Family
ID=10807887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19993953A NO322653B1 (no) | 1997-02-18 | 1999-08-17 | Fremgangsmate for femstilling av et in vitro peptid- eller proteinekspresjonsbibliotek, peptid- eller proteinekspresjonsbibliotek, fremgangsmate for a identifisere et malmolekyl, samt bifunksjonell molekylaer probe for anvendelse i en slik fremgangsmate. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7416847B1 (ja) |
| EP (1) | EP1007654B1 (ja) |
| JP (1) | JP4644321B2 (ja) |
| AT (1) | ATE297462T1 (ja) |
| AU (1) | AU744791B2 (ja) |
| CA (1) | CA2282497C (ja) |
| DE (2) | DE1007654T1 (ja) |
| DK (1) | DK1007654T3 (ja) |
| ES (1) | ES2241117T3 (ja) |
| GB (1) | GB9703369D0 (ja) |
| IL (2) | IL131435A0 (ja) |
| NO (1) | NO322653B1 (ja) |
| PT (1) | PT1007654E (ja) |
| WO (1) | WO1998037186A1 (ja) |
Families Citing this family (238)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69835143T2 (de) | 1997-01-21 | 2007-06-06 | The General Hospital Corp., Boston | Selektion von proteinen mittels rns-protein fusionen |
| US8207093B2 (en) | 1997-01-21 | 2012-06-26 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
| US6261804B1 (en) | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
| EP1496120B1 (en) * | 1997-07-07 | 2007-03-28 | Medical Research Council | In vitro sorting method |
| CA2337490C (en) | 1998-08-17 | 2012-01-03 | Phylos, Inc. | Identification of compound-protein interactions using libraries of protein-nucleic acid fusion molecules |
| DE69935248T2 (de) | 1998-12-02 | 2007-11-08 | Adnexus Therapeutics, Inc., Waltham | Dna-protein fusionen sowie anwendungen derselben |
| JP2003500081A (ja) | 1999-06-01 | 2003-01-07 | フィロス インク． | ５’核酸−タンパク質結合体の生成法 |
| WO2001025249A1 (en) * | 1999-10-01 | 2001-04-12 | Zhongping Yu | Compositions and methods for identifying polypeptides and nucleic acid molecules |
| CA2396810A1 (en) * | 2000-01-24 | 2001-07-26 | Phylos, Inc. | Sensitive, multiplexed diagnostic assays for protein analysis |
| GB2360282A (en) * | 2000-03-17 | 2001-09-19 | Bioinvent Int Ab | Making and using micro-arrays of biological materials |
| WO2002022826A2 (en) * | 2000-09-14 | 2002-03-21 | Xencor, Inc. | Methods and compositions for the construction and use of fusion libraries |
| US20030124537A1 (en) * | 2000-12-14 | 2003-07-03 | Yuan-Chin Liu | Procaryotic libraries and uses |
| WO2002068453A2 (en) * | 2001-02-22 | 2002-09-06 | Xencor | Methods and compositions for the construction and use of fusion libraries using computational protein design methods |
| US20020168640A1 (en) * | 2001-02-22 | 2002-11-14 | Min Li | Biochips comprising nucleic acid/protein conjugates |
| CA2440649A1 (en) | 2001-03-07 | 2002-09-19 | Children's Medical Center Corporation | Method to screen peptide display libraries using minicell display |
| GB0127564D0 (en) | 2001-11-16 | 2002-01-09 | Medical Res Council | Emulsion compositions |
| WO2004022746A1 (en) | 2002-09-06 | 2004-03-18 | Isogenica Limited | In vitro peptide expression libraray |
| AU2002368488A1 (en) * | 2002-12-23 | 2004-07-14 | Affitech As | Process for producing an in vitro peptide expression library |
| MXPA05006724A (es) | 2003-01-07 | 2005-09-08 | Symphogen As | Metodo para producir proteinas policlonales recombinantes. |
| EP2159285B1 (en) | 2003-01-29 | 2012-09-26 | 454 Life Sciences Corporation | Methods of amplifying and sequencing nucleic acids |
| GB0307403D0 (en) | 2003-03-31 | 2003-05-07 | Medical Res Council | Selection by compartmentalised screening |
| US20060078893A1 (en) | 2004-10-12 | 2006-04-13 | Medical Research Council | Compartmentalised combinatorial chemistry by microfluidic control |
| GB0307428D0 (en) | 2003-03-31 | 2003-05-07 | Medical Res Council | Compartmentalised combinatorial chemistry |
| EP1641809B2 (en) | 2003-07-05 | 2018-10-03 | The Johns Hopkins University | Method and compositions for detection and enumeration of genetic variations |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US20120196370A1 (en) | 2010-12-03 | 2012-08-02 | Fyodor Urnov | Methods and compositions for targeted genomic deletion |
| CA2534296C (en) | 2003-08-08 | 2013-03-26 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US20070134796A1 (en) | 2005-07-26 | 2007-06-14 | Sangamo Biosciences, Inc. | Targeted integration and expression of exogenous nucleic acid sequences |
| WO2005042743A2 (en) | 2003-08-18 | 2005-05-12 | Medimmune, Inc. | Humanization of antibodies |
| JP4430076B2 (ja) * | 2003-10-01 | 2010-03-10 | イーティーエイチ・チューリッヒ | ポリペプチドの試験管内進化方法 |
| US20050221339A1 (en) | 2004-03-31 | 2005-10-06 | Medical Research Council Harvard University | Compartmentalised screening by microfluidic control |
| CA2574062A1 (en) | 2004-07-20 | 2006-01-26 | Symphogen A/S | Anti-rhesus d recombinant polyclonal antibody and methods of manufacture |
| US7968287B2 (en) | 2004-10-08 | 2011-06-28 | Medical Research Council Harvard University | In vitro evolution in microfluidic systems |
| AU2006227377B2 (en) | 2005-03-18 | 2013-01-31 | Medimmune, Llc | Framework-shuffling of antibodies |
| US20090263900A1 (en) | 2008-04-14 | 2009-10-22 | Sangamo Biosciences, Inc. | Linear donor constructs for targeted integration |
| EP1984738A2 (en) | 2006-01-11 | 2008-10-29 | Raindance Technologies, Inc. | Microfluidic devices and methods of use in the formation and control of nanoreactors |
| GB0605584D0 (en) | 2006-03-20 | 2006-04-26 | Olink Ab | Method for analyte detection using proximity probes |
| US9562837B2 (en) | 2006-05-11 | 2017-02-07 | Raindance Technologies, Inc. | Systems for handling microfludic droplets |
| EP2481815B1 (en) | 2006-05-11 | 2016-01-27 | Raindance Technologies, Inc. | Microfluidic devices |
| WO2007139982A2 (en) * | 2006-05-25 | 2007-12-06 | Sangamo Biosciences, Inc. | Methods and compositions for gene inactivation |
| EP3536396B1 (en) | 2006-08-07 | 2022-03-30 | The President and Fellows of Harvard College | Fluorocarbon emulsion stabilizing surfactants |
| EP2049663B1 (en) | 2006-08-11 | 2015-02-25 | Dow AgroSciences LLC | Zinc finger nuclease-mediated homologous recombination |
| AU2007334468B2 (en) | 2006-12-14 | 2013-02-07 | Corteva Agriscience Llc | Optimized non-canonical zinc finger proteins |
| US8772046B2 (en) | 2007-02-06 | 2014-07-08 | Brandeis University | Manipulation of fluids and reactions in microfluidic systems |
| CN101680896A (zh) | 2007-03-27 | 2010-03-24 | 伊缪诺维亚公司 | 检测腺癌的蛋白标志/标记 |
| US8592221B2 (en) | 2007-04-19 | 2013-11-26 | Brandeis University | Manipulation of fluids, fluid components and reactions in microfluidic systems |
| CN101679977B (zh) | 2007-04-26 | 2013-05-01 | 桑格摩生物科学股份有限公司 | 向ppp1r12c基因座的靶向整合 |
| SI2152872T1 (sl) | 2007-05-25 | 2011-01-31 | Symphogen As | Postopek za pripravo rekombinantnega poliklonskega proteina |
| KR101510778B1 (ko) | 2007-07-12 | 2015-04-10 | 상가모 바이오사이언스 인코포레이티드 | 알파 1,6 당전이효소(ｆｕｔ8) 유전자 발현을 비활성화시키기 위한 방법 및 조성물 |
| CN101878307B (zh) | 2007-09-27 | 2017-07-28 | 陶氏益农公司 | 以5‑烯醇式丙酮酰莽草酸‑3‑磷酸合酶基因为靶的改造锌指蛋白 |
| US8563314B2 (en) | 2007-09-27 | 2013-10-22 | Sangamo Biosciences, Inc. | Methods and compositions for modulating PD1 |
| CA2700231C (en) | 2007-09-27 | 2018-09-18 | Sangamo Biosciences, Inc. | Rapid in vivo identification of biologically active nucleases |
| US11235026B2 (en) | 2007-09-27 | 2022-02-01 | Sangamo Therapeutics, Inc. | Methods and compositions for modulating PD1 |
| EP2205752B1 (en) | 2007-10-25 | 2016-08-10 | Sangamo BioSciences, Inc. | Methods and compositions for targeted integration |
| WO2009134409A2 (en) | 2008-04-30 | 2009-11-05 | Sanbio, Inc. | Neural regenerating cells with alterations in dna methylation |
| JP2011521643A (ja) | 2008-05-28 | 2011-07-28 | サンガモ バイオサイエンシーズ， インコーポレイテッド | Ｄｎａ結合ドメインおよび切断ドメインを連結するための組成物 |
| US8597912B2 (en) | 2008-06-10 | 2013-12-03 | Sangamo Biosciences, Inc. | Methods and compositions for generation of Bax-and Bak-deficient cell lines |
| US12038438B2 (en) | 2008-07-18 | 2024-07-16 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
| EP4047367A1 (en) | 2008-07-18 | 2022-08-24 | Bio-Rad Laboratories, Inc. | Method for detecting target analytes with droplet libraries |
| CN102177438A (zh) * | 2008-07-25 | 2011-09-07 | 理查德·W·瓦格纳 | 蛋白筛选方法 |
| KR20160015400A (ko) | 2008-08-22 | 2016-02-12 | 상가모 바이오사이언스 인코포레이티드 | 표적화된 단일가닥 분할 및 표적화된 통합을 위한 방법 및 조성물 |
| CA2741119C (en) | 2008-10-29 | 2019-02-12 | Sangamo Biosciences, Inc. | Methods and compositions for inactivating glutamine synthetase gene expression |
| EP2356270B1 (en) | 2008-11-07 | 2016-08-24 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
| CN102625655B (zh) | 2008-12-04 | 2016-07-06 | 桑格摩生物科学股份有限公司 | 使用锌指核酸酶在大鼠中进行基因组编辑 |
| DK2370575T3 (en) | 2008-12-17 | 2018-02-05 | Dow Agrosciences Llc | TARGETED INTEGRATION IN THE ZP15 LOCUS |
| AU2010211057B2 (en) | 2009-02-04 | 2014-12-18 | Sangamo Therapeutics, Inc. | Methods and compositions for treating neuropathies |
| US8871905B2 (en) | 2009-03-20 | 2014-10-28 | Sangamo Biosciences, Inc. | Modification of CXCR4 using engineered zinc finger proteins |
| US8528589B2 (en) | 2009-03-23 | 2013-09-10 | Raindance Technologies, Inc. | Manipulation of microfluidic droplets |
| WO2010117464A1 (en) | 2009-04-09 | 2010-10-14 | Sangamo Biosciences, Inc. | Targeted integration into stem cells |
| US8772008B2 (en) | 2009-05-18 | 2014-07-08 | Sangamo Biosciences, Inc. | Methods and compositions for increasing nuclease activity |
| JP5798116B2 (ja) | 2009-06-30 | 2015-10-21 | サンガモ バイオサイエンシーズ， インコーポレイテッド | 生物活性のあるヌクレアーゼの迅速なスクリーニングおよびヌクレアーゼ修飾細胞の単離 |
| EP2451837B1 (en) | 2009-07-08 | 2015-03-25 | Cellular Dynamics International, Inc. | Modified ips cells having a mutant form of human immunodeficiency virus (hiv) cellular entry gene |
| AU2010281705B2 (en) | 2009-07-28 | 2015-02-05 | Sangamo Therapeutics, Inc. | Methods and compositions for treating trinucleotide repeat disorders |
| EP2462230B1 (en) * | 2009-08-03 | 2015-07-15 | Recombinetics, Inc. | Methods and compositions for targeted gene modification |
| US20110041195A1 (en) | 2009-08-11 | 2011-02-17 | Sangamo Biosciences, Inc. | Organisms homozygous for targeted modification |
| BR112012005485A2 (pt) * | 2009-09-10 | 2016-04-19 | Lonza Biologics Plc | método e sistema para a purificação de polipeptídeo |
| WO2011042564A1 (en) | 2009-10-09 | 2011-04-14 | Universite De Strasbourg | Labelled silica-based nanomaterial with enhanced properties and uses thereof |
| EP2491127B1 (en) | 2009-10-22 | 2017-09-20 | Dow AgroSciences LLC | Engineered zinc finger proteins targeting plant genes involved in fatty acid biosynthesis |
| US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| WO2011079176A2 (en) | 2009-12-23 | 2011-06-30 | Raindance Technologies, Inc. | Microfluidic systems and methods for reducing the exchange of molecules between droplets |
| MX336846B (es) | 2010-01-22 | 2016-02-03 | Sangamo Biosciences Inc | Alteracion genomica dirigida. |
| JP2013518602A (ja) | 2010-02-09 | 2013-05-23 | サンガモ バイオサイエンシーズ， インコーポレイテッド | 部分的に一本鎖のドナー分子による標的化ゲノム改変 |
| US9399797B2 (en) | 2010-02-12 | 2016-07-26 | Raindance Technologies, Inc. | Digital analyte analysis |
| WO2011100604A2 (en) | 2010-02-12 | 2011-08-18 | Raindance Technologies, Inc. | Digital analyte analysis |
| US10351905B2 (en) | 2010-02-12 | 2019-07-16 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
| US9366632B2 (en) | 2010-02-12 | 2016-06-14 | Raindance Technologies, Inc. | Digital analyte analysis |
| GB201004292D0 (en) | 2010-03-15 | 2010-04-28 | Olink Ab | Assay for localised detection of analytes |
| US8771985B2 (en) | 2010-04-26 | 2014-07-08 | Sangamo Biosciences, Inc. | Genome editing of a Rosa locus using zinc-finger nucleases |
| HUE048072T2 (hu) | 2010-05-03 | 2020-05-28 | Sangamo Therapeutics Inc | Készítmények cinkujj-modulok összekapcsolására |
| EP3156062A1 (en) | 2010-05-17 | 2017-04-19 | Sangamo BioSciences, Inc. | Novel dna-binding proteins and uses thereof |
| GB201009798D0 (en) | 2010-06-11 | 2010-07-21 | Immunovia Ab | Method,array and use thereof |
| GB201011971D0 (en) | 2010-07-15 | 2010-09-01 | Olink Ab | Methods and product |
| EP2596011B1 (en) | 2010-07-21 | 2018-10-03 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of a hla locus |
| KR20180121665A (ko) | 2010-07-23 | 2018-11-07 | 시그마-알드리치 컴퍼니., 엘엘씨 | 표적화 엔도뉴클레아제 및 단일-가닥 핵산을 사용하는 게놈 편집 |
| GB201014837D0 (en) | 2010-09-07 | 2010-10-20 | Immunovia Ab | Biomarker signatures and uses thereof |
| AU2011312562B2 (en) | 2010-09-27 | 2014-10-09 | Sangamo Therapeutics, Inc. | Methods and compositions for inhibiting viral entry into cells |
| WO2012045012A2 (en) | 2010-09-30 | 2012-04-05 | Raindance Technologies, Inc. | Sandwich assays in droplets |
| CA2814143C (en) | 2010-10-12 | 2020-09-08 | The Children's Hospital Of Philadelphia | Methods and compositions for treating hemophilia b |
| EP2627781B1 (en) | 2010-10-15 | 2017-02-22 | Olink Bioscience AB | Dynamic range methods |
| GB201018014D0 (en) | 2010-10-26 | 2010-12-08 | Senzagen Ab | Analytical methods and arrays for use in the same |
| EP2466310A1 (en) | 2010-12-17 | 2012-06-20 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | Means and methods for detecting double-strand breaks |
| EP2659404B1 (en) | 2010-12-29 | 2018-08-08 | Sigma-Aldrich Co., LLC | Cells having disrupted expression of proteins involved in adme and toxicology processes |
| US9267123B2 (en) | 2011-01-05 | 2016-02-23 | Sangamo Biosciences, Inc. | Methods and compositions for gene correction |
| GB201101621D0 (en) | 2011-01-31 | 2011-03-16 | Olink Ab | Method and product |
| WO2012109600A2 (en) | 2011-02-11 | 2012-08-16 | Raindance Technologies, Inc. | Methods for forming mixed droplets |
| WO2012112804A1 (en) | 2011-02-18 | 2012-08-23 | Raindance Technoligies, Inc. | Compositions and methods for molecular labeling |
| GB201103726D0 (en) | 2011-03-04 | 2011-04-20 | Immunovia Ab | Method, array and use thereof |
| US20140186340A1 (en) | 2011-04-08 | 2014-07-03 | Gilead Biologics, Inc. | Methods and Compositions for Normalization of Tumor Vasculature by Inhibition of LOXL2 |
| GB201107863D0 (en) | 2011-05-11 | 2011-06-22 | Olink Ab | Method and product |
| US8841071B2 (en) | 2011-06-02 | 2014-09-23 | Raindance Technologies, Inc. | Sample multiplexing |
| EP3709018A1 (en) | 2011-06-02 | 2020-09-16 | Bio-Rad Laboratories, Inc. | Microfluidic apparatus for identifying components of a chemical reaction |
| US8980583B2 (en) | 2011-06-30 | 2015-03-17 | Sigma-Aldrich Co. Llc | Cells deficient in CMP-N-acetylneuraminic acid hydroxylase and/or glycoprotein alpha-1,3-galactosyltransferase |
| US8658430B2 (en) | 2011-07-20 | 2014-02-25 | Raindance Technologies, Inc. | Manipulating droplet size |
| WO2013016446A2 (en) | 2011-07-25 | 2013-01-31 | Sangamo Biosciences, Inc. | Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (cftr) gene |
| CN103917644A (zh) | 2011-09-21 | 2014-07-09 | 桑格摩生物科学股份有限公司 | 调控转基因表达的方法和组合物 |
| US20130090247A1 (en) | 2011-10-11 | 2013-04-11 | Biolauncher Ltd. | Methods and systems for identification of binding pharmacophores |
| US20130090265A1 (en) | 2011-10-11 | 2013-04-11 | Biolauncher Ltd. | Systems and methods for generation of context-specific, molecular field-based amino acid substitution matrices |
| US20130090266A1 (en) | 2011-10-11 | 2013-04-11 | Biolauncher Ltd. | Methods and systems for optimization of peptide screening |
| JP6188703B2 (ja) | 2011-10-27 | 2017-08-30 | サンガモ セラピューティクス， インコーポレイテッド | Ｈｐｒｔ遺伝子座を修飾するための方法および組成物 |
| EP2780460B1 (en) | 2011-11-16 | 2018-07-11 | Sangamo Therapeutics, Inc. | Modified dna-binding proteins and uses thereof |
| GB201122325D0 (en) | 2011-12-23 | 2012-02-01 | Cytoguide As | Novel formulations |
| CN104245932A (zh) | 2012-01-11 | 2014-12-24 | 西格马-奥尔德里奇有限责任公司 | 具有简单糖型的重组蛋白的产生 |
| CN112386681A (zh) | 2012-01-27 | 2021-02-23 | 桑比欧公司 | 用于调节血管生成和血管发生的方法和组合物 |
| GB201201547D0 (en) | 2012-01-30 | 2012-03-14 | Olink Ab | Method and product |
| US10570378B2 (en) | 2012-02-28 | 2020-02-25 | Sigma-Aldrich Co. Llc | Targeted histone acetylation |
| AU2013225950B2 (en) | 2012-02-29 | 2018-02-15 | Sangamo Therapeutics, Inc. | Methods and compositions for treating huntington's disease |
| GB2500243A (en) * | 2012-03-15 | 2013-09-18 | Isogenica Ltd | Identifying members of immobilised peptide libraries comprising protein-DNA complexes |
| GB201207297D0 (en) | 2012-04-26 | 2012-06-06 | Senzagen Ab | Analytical methods and arrays for use in the same |
| AU2013256240B2 (en) | 2012-05-02 | 2018-09-20 | Corteva Agriscience Llc | Targeted modification of malate dehydrogenase |
| CN104471067B (zh) | 2012-05-07 | 2020-08-14 | 桑格摩生物治疗股份有限公司 | 用于核酸酶介导的转基因靶向整合的方法和组合物 |
| US10648001B2 (en) | 2012-07-11 | 2020-05-12 | Sangamo Therapeutics, Inc. | Method of treating mucopolysaccharidosis type I or II |
| EP3196301B1 (en) | 2012-07-11 | 2018-10-17 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of monogenic diseases |
| JP6329537B2 (ja) | 2012-07-11 | 2018-05-23 | サンガモ セラピューティクス， インコーポレイテッド | 生物学的薬剤の送達のための方法および組成物 |
| DK2890780T3 (da) | 2012-08-29 | 2020-09-21 | Sangamo Therapeutics Inc | Fremgangsmåder og sammensætninger til behandling af en genetisk tilstand |
| WO2014039513A2 (en) | 2012-09-04 | 2014-03-13 | The Trustees Of The University Of Pennsylvania | Inhibition of diacylglycerol kinase to augment adoptive t cell transfer |
| UA119135C2 (uk) | 2012-09-07 | 2019-05-10 | ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі | Спосіб отримання трансгенної рослини |
| JP6775953B2 (ja) | 2012-09-07 | 2020-10-28 | ダウ アグロサイエンシィズ エルエルシー | Ｆａｄ３性能座および標的化切断を誘導可能である対応する標的部位特異的結合タンパク質 |
| UA118090C2 (uk) | 2012-09-07 | 2018-11-26 | ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі | Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив |
| EP3763810A3 (en) | 2012-10-10 | 2021-07-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| US9255250B2 (en) | 2012-12-05 | 2016-02-09 | Sangamo Bioscience, Inc. | Isolated mouse or human cell having an exogenous transgene in an endogenous albumin gene |
| JP2016500268A (ja) | 2012-12-13 | 2016-01-12 | ダウ アグロサイエンシィズ エルエルシー | トウモロコシにおける特定の遺伝子座に対する精密な遺伝子標的化 |
| EP2963113B1 (en) | 2013-02-14 | 2019-11-06 | Osaka University | Method for isolating specific genomic region using molecule binding specifically to endogenous dna sequence |
| US10227610B2 (en) | 2013-02-25 | 2019-03-12 | Sangamo Therapeutics, Inc. | Methods and compositions for enhancing nuclease-mediated gene disruption |
| WO2014153470A2 (en) | 2013-03-21 | 2014-09-25 | Sangamo Biosciences, Inc. | Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases |
| GB201305940D0 (en) | 2013-04-02 | 2013-05-15 | Immunovia Ab | Methods and arrays for use in the same |
| KR102192599B1 (ko) | 2013-04-05 | 2020-12-18 | 다우 아그로사이언시즈 엘엘씨 | 식물의 게놈 내의 외인성 서열의 통합을 위한 방법 및 조성물 |
| AU2014262867B2 (en) | 2013-05-10 | 2019-12-05 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| CN116083487A (zh) | 2013-05-15 | 2023-05-09 | 桑格摩生物治疗股份有限公司 | 用于治疗遗传病状的方法和组合物 |
| EP3988654A1 (en) | 2013-08-28 | 2022-04-27 | Sangamo Therapeutics, Inc. | Compositions for linking dna-binding domains and cleavage domains |
| US11901041B2 (en) | 2013-10-04 | 2024-02-13 | Bio-Rad Laboratories, Inc. | Digital analysis of nucleic acid modification |
| EP3057432B1 (en) | 2013-10-17 | 2018-11-21 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells |
| ES2881473T3 (es) | 2013-10-17 | 2021-11-29 | Sangamo Therapeutics Inc | Métodos de suministro y composiciones para la modificación por ingeniería genética del genoma mediada por nucleasas |
| GB201319878D0 (en) | 2013-11-11 | 2013-12-25 | Immunovia Ab | Method, Array and use thereof |
| CN105934524A (zh) | 2013-11-11 | 2016-09-07 | 桑格摩生物科学股份有限公司 | 用于治疗亨廷顿氏病的方法和组合物 |
| PL3492593T3 (pl) | 2013-11-13 | 2022-04-19 | Children's Medical Center Corporation | Regulacja ekspresji genów, w której pośredniczą nukleazy |
| EP3757116A1 (en) | 2013-12-09 | 2020-12-30 | Sangamo Therapeutics, Inc. | Methods and compositions for genome engineering |
| US9944977B2 (en) | 2013-12-12 | 2018-04-17 | Raindance Technologies, Inc. | Distinguishing rare variations in a nucleic acid sequence from a sample |
| EP3090063B1 (en) | 2013-12-31 | 2019-11-06 | Bio-Rad Laboratories, Inc. | Method for detection of latent retrovirus |
| WO2015117081A2 (en) | 2014-02-03 | 2015-08-06 | Sangamo Biosciences, Inc. | Methods and compositions for treatment of a beta thalessemia |
| AU2015218576B2 (en) | 2014-02-24 | 2020-02-27 | Sangamo Therapeutics, Inc. | Methods and compositions for nuclease-mediated targeted integration |
| EP3114222B1 (en) | 2014-03-04 | 2020-04-22 | Sigma Aldrich Co. LLC | Viral resistant cells and uses thereof |
| CA2942762C (en) | 2014-03-18 | 2023-10-17 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of zinc finger protein expression |
| US9522936B2 (en) | 2014-04-24 | 2016-12-20 | Sangamo Biosciences, Inc. | Engineered transcription activator like effector (TALE) proteins |
| EP3142707A4 (en) | 2014-05-13 | 2018-02-21 | Sangamo Therapeutics, Inc. | Methods and compositions for prevention or treatment of a disease |
| WO2015188065A1 (en) | 2014-06-05 | 2015-12-10 | Sangamo Biosciences, Inc. | Methods and compositions for nuclease design |
| GB201410226D0 (en) | 2014-06-09 | 2014-07-23 | Immunovia Ab | Methods and arrays for use in the same |
| ES2965286T3 (es) | 2014-07-14 | 2024-04-12 | Univ Washington State | Silenciamiento de NANOS que abate las células germinales |
| US9757420B2 (en) | 2014-07-25 | 2017-09-12 | Sangamo Therapeutics, Inc. | Gene editing for HIV gene therapy |
| WO2016014794A1 (en) | 2014-07-25 | 2016-01-28 | Sangamo Biosciences, Inc. | Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells |
| WO2016019144A2 (en) | 2014-07-30 | 2016-02-04 | Sangamo Biosciences, Inc. | Gene correction of scid-related genes in hematopoietic stem and progenitor cells |
| RS62334B1 (sr) | 2014-09-16 | 2021-10-29 | Sangamo Therapeutics Inc | Postupci i sastavi za inženjering genoma posredovan nukleazom i korekciju kod matičnih ćelija hematopoeze |
| US10889834B2 (en) | 2014-12-15 | 2021-01-12 | Sangamo Therapeutics, Inc. | Methods and compositions for enhancing targeted transgene integration |
| WO2016118726A2 (en) | 2015-01-21 | 2016-07-28 | Sangamo Biosciences, Inc. | Methods and compositions for identification of highly specific nucleases |
| CA2981077A1 (en) | 2015-04-03 | 2016-10-06 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
| US10179918B2 (en) | 2015-05-07 | 2019-01-15 | Sangamo Therapeutics, Inc. | Methods and compositions for increasing transgene activity |
| BR112017024115A2 (pt) | 2015-05-12 | 2018-08-07 | Sangamo Therapeutics Inc | regulação de expressão genética mediada por nuclease |
| US9957501B2 (en) | 2015-06-18 | 2018-05-01 | Sangamo Therapeutics, Inc. | Nuclease-mediated regulation of gene expression |
| EP3322297A4 (en) | 2015-07-13 | 2019-04-17 | Sangamo Therapeutics, Inc. | RELEASE METHOD AND COMPOSITIONS FOR NUCLEASE-DERIVED GENOMINE ENGINEERING |
| LT3331355T (lt) | 2015-08-06 | 2024-07-25 | The Curators Of The University Of Missouri | Kiaulių reprodukcinio ir respiracinio sindromo virusui (prrsv) atsparios kiaulės ir ląstelės, turinčios modifikuotus cd163 genus |
| US10647981B1 (en) | 2015-09-08 | 2020-05-12 | Bio-Rad Laboratories, Inc. | Nucleic acid library generation methods and compositions |
| GB201516801D0 (en) | 2015-09-22 | 2015-11-04 | Immunovia Ab | Method, array and use thereof |
| WO2018057051A1 (en) | 2016-09-24 | 2018-03-29 | Abvitro Llc | Affinity-oligonucleotide conjugates and uses thereof |
| AU2016326737B2 (en) | 2015-09-24 | 2023-01-12 | Abvitro Llc | Affinity-oligonucleotide conjugates and uses thereof |
| CA3002674A1 (en) | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
| AU2016343805A1 (en) | 2015-10-30 | 2018-06-07 | Aleta Biotherapeutics Inc. | Compositions and methods for tumor transduction |
| EP3380622A4 (en) | 2015-11-23 | 2019-08-07 | Sangamo Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODIFYING IMMUNITY |
| EP3389677B1 (en) | 2015-12-18 | 2024-06-26 | Sangamo Therapeutics, Inc. | Targeted disruption of the t cell receptor |
| JP2018537112A (ja) | 2015-12-18 | 2018-12-20 | サンガモ セラピューティクス， インコーポレイテッド | Ｍｈｃ細胞受容体の標的化破壊 |
| JP6930052B2 (ja) | 2016-01-15 | 2021-09-01 | サンガモ セラピューティクス， インコーポレイテッド | 神経性疾患の処置のための方法および組成物 |
| EP3411056A4 (en) | 2016-02-02 | 2019-10-02 | Sangamo Therapeutics, Inc. | COMPOUNDS FOR NETWORKING DNA BINDING DOMAINS AND SPLITTING DOMAINS |
| GB201700138D0 (en) | 2017-01-05 | 2017-02-22 | Senzagen Ab | Analytical methods and arrays for use in the same |
| EP3536805B1 (en) | 2016-03-23 | 2022-11-02 | SenzaGen AB | Analytical methods and arrays for use in the same |
| GB201608192D0 (en) | 2016-05-10 | 2016-06-22 | Immunovia Ab | Method, array and use thereof |
| GB201609951D0 (en) | 2016-06-07 | 2016-07-20 | Immunovia Ab | Biomarkers signatures and uses thereof |
| GB201609950D0 (en) | 2016-06-07 | 2016-07-20 | Immunovia Ab | Biomarkers signatures and uses thereof |
| US20200182884A1 (en) | 2016-06-27 | 2020-06-11 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
| MA45491A (fr) | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés |
| US11124805B2 (en) | 2016-07-13 | 2021-09-21 | Vertex Pharmaceuticals Incorporated | Methods, compositions and kits for increasing genome editing efficiency |
| KR20230088522A (ko) | 2016-07-21 | 2023-06-19 | 맥스시티 인코포레이티드 | 게놈 dna를 변경하기 위한 방법 및 조성물 |
| KR20220145913A (ko) | 2016-08-24 | 2022-10-31 | 상가모 테라퓨틱스, 인코포레이티드 | 가공된 표적 특이적 뉴클레아제 |
| PE20190568A1 (es) | 2016-08-24 | 2019-04-22 | Sangamo Therapeutics Inc | Regulacion de la expresion genica usando nucleasas modificadas |
| US11219695B2 (en) | 2016-10-20 | 2022-01-11 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of Fabry disease |
| US11020492B2 (en) | 2016-10-31 | 2021-06-01 | Sangamo Therapeutics, Inc. | Gene correction of SCID-related genes in hematopoietic stem and progenitor cells |
| WO2018106782A1 (en) | 2016-12-08 | 2018-06-14 | Case Western Reserve University | Methods and compositions for enhancing functional myelin production |
| WO2018140478A1 (en) | 2017-01-24 | 2018-08-02 | Sigma-Aldrich Co. Llc | Viral resistant cells and culture systems |
| GB201706464D0 (en) | 2017-04-24 | 2017-06-07 | Senzagen Ab | Analytical methods and arrays for use in the same |
| WO2018204469A2 (en) | 2017-05-03 | 2018-11-08 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (cftr) gene |
| US11512287B2 (en) | 2017-06-16 | 2022-11-29 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell and/or HLA receptors |
| KR20200079539A (ko) | 2017-11-09 | 2020-07-03 | 상가모 테라퓨틱스, 인코포레이티드 | 시토카인 유도성 sh2-함유 단백질 (cish) 유전자의 유전자 변형 |
| JP2021508443A (ja) | 2017-12-15 | 2021-03-11 | アレタ・バイオセラピューティクス・インコーポレイテッドＡｌｅｔａ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | Ｃｄ１９変異体 |
| CA3088791A1 (en) | 2018-01-17 | 2019-07-25 | Vertex Pharmaceuticals Incorporated | Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency |
| CN111741955B (zh) | 2018-01-17 | 2024-02-23 | 沃泰克斯药物股份有限公司 | Dna-pk抑制剂 |
| MA51619A (fr) | 2018-01-17 | 2021-04-14 | Vertex Pharma | Inhibiteurs de la protéine kinase dépendante de l'adn |
| EP3749350A4 (en) | 2018-02-08 | 2021-12-01 | Sangamo Therapeutics, Inc. | SPECIFICALLY MODIFIED TARGET-SPECIFIC NUCLEASES |
| US11421007B2 (en) | 2018-04-18 | 2022-08-23 | Sangamo Therapeutics, Inc. | Zinc finger protein compositions for modulation of huntingtin (Htt) |
| US11690921B2 (en) | 2018-05-18 | 2023-07-04 | Sangamo Therapeutics, Inc. | Delivery of target specific nucleases |
| AU2019326408A1 (en) | 2018-08-23 | 2021-03-11 | Sangamo Therapeutics, Inc. | Engineered target specific base editors |
| EP3853244A4 (en) | 2018-09-18 | 2022-09-14 | Sangamo Therapeutics, Inc. | PROGRAMMED CELL DEATH 1 (PD1) SPECIFIC NUCLEASES |
| KR20210111261A (ko) | 2019-01-03 | 2021-09-10 | 센자겐 아베 | 호흡기 감작을 유도할 수 있는 작용제의 식별 방법 및 그 방법에 사용하기 위한 어레이 및 분석용 키트 |
| JP7523449B2 (ja) | 2019-01-11 | 2024-07-26 | アクイタス セラピューティクス インコーポレイテッド | 活性剤の脂質ナノ粒子送達のための脂質 |
| US11857641B2 (en) | 2019-02-06 | 2024-01-02 | Sangamo Therapeutics, Inc. | Method for the treatment of mucopolysaccharidosis type I |
| WO2020205838A1 (en) | 2019-04-02 | 2020-10-08 | Sangamo Therapeutics, Inc. | Methods for the treatment of beta-thalassemia |
| MX2021015057A (es) | 2019-06-13 | 2022-01-18 | Allogene Therapeutics Inc | Anticuerpos anti-talen y usos de los mismos. |
| CN115803435A (zh) | 2020-05-06 | 2023-03-14 | 塞勒克提斯公司 | 用于在细胞基因组中靶向插入外源序列的方法 |
| US20230279440A1 (en) | 2020-05-06 | 2023-09-07 | Cellectis S.A. | Methods to genetically modify cells for delivery of therapeutic proteins |
| GB202010970D0 (en) | 2020-07-16 | 2020-09-02 | Immunovia Ab | Methods, arrays and uses thereof |
| AU2021308681A1 (en) | 2020-07-16 | 2023-03-09 | Acuitas Therapeutics, Inc. | Cationic lipids for use in lipid nanoparticles |
| EP4204545A2 (en) | 2020-08-25 | 2023-07-05 | Kite Pharma, Inc. | T cells with improved functionality |
| US20240000051A1 (en) | 2020-11-16 | 2024-01-04 | Pig Improvement Company Uk Limited | Influenza a-resistant animals having edited anp32 genes |
| JP2024533311A (ja) | 2021-09-08 | 2024-09-12 | フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー | ゲノムを調節するための方法及び組成物 |
| CN118401257A (zh) | 2021-11-09 | 2024-07-26 | 美国安进公司 | 用于产生抗体肽缀合物的方法 |
| WO2023105244A1 (en) | 2021-12-10 | 2023-06-15 | Pig Improvement Company Uk Limited | Editing tmprss2/4 for disease resistance in livestock |
| WO2023168397A1 (en) | 2022-03-04 | 2023-09-07 | Sigma-Aldrich Co. Llc | Metabolic selection via the asparagine biosynthesis pathway |
| WO2024013514A2 (en) | 2022-07-15 | 2024-01-18 | Pig Improvement Company Uk Limited | Gene edited livestock animals having coronavirus resistance |
| WO2024073692A1 (en) | 2022-09-30 | 2024-04-04 | Sigma-Aldrich Co. Llc | Metabolic selection via the glycine-formate biosynthesis pathway |
| WO2024073686A1 (en) | 2022-09-30 | 2024-04-04 | Sigma-Aldrich Co. Llc | Metabolic selection via the serine biosynthesis pathway |
| EP4382534A1 (en) | 2022-12-06 | 2024-06-12 | Biomérieux | Synthetic peptide for use in an immunomolecular assay |
| WO2024156899A1 (en) | 2023-01-27 | 2024-08-02 | Biomerieux | Modified immuno-molecular assay for faster biomarker detection |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8824592D0 (en) * | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Purification process |
| DK0494955T3 (da) * | 1989-10-05 | 1998-10-26 | Optein Inc | Cellefri syntese og isolering af hidtil ukendte gener og polypeptider |
| AU8498091A (en) * | 1990-08-02 | 1992-03-02 | Regents Of The University Of Colorado, The | Systematic polypeptide evolution by reverse translation |
| WO1993003172A1 (en) * | 1991-08-01 | 1993-02-18 | University Research Corporation | Systematic polypeptide evolution by reverse translation |
| US5270170A (en) * | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| US5922545A (en) * | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
| US5627024A (en) * | 1994-08-05 | 1997-05-06 | The Scripps Research Institute | Lambdoid bacteriophage vectors for expression and display of foreign proteins |
| DE19646372C1 (de) * | 1995-11-11 | 1997-06-19 | Evotec Biosystems Gmbh | Genotyp und Phänotyp koppelnde Verbindung |
| US7138511B1 (en) * | 1997-01-28 | 2006-11-21 | The Regents Of The University Of California | Nucleic acids, kits and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders |
| US6100035A (en) * | 1998-07-14 | 2000-08-08 | Cistem Molecular Corporation | Method of identifying cis acting nucleic acid elements |
-
1997
- 1997-02-18 GB GBGB9703369.0A patent/GB9703369D0/en active Pending
-
1998
- 1998-02-18 AT AT98905520T patent/ATE297462T1/de active
- 1998-02-18 JP JP53638498A patent/JP4644321B2/ja not_active Expired - Fee Related
- 1998-02-18 ES ES98905520T patent/ES2241117T3/es not_active Expired - Lifetime
- 1998-02-18 EP EP98905520A patent/EP1007654B1/en not_active Expired - Lifetime
- 1998-02-18 DK DK98905520T patent/DK1007654T3/da active
- 1998-02-18 DE DE1007654T patent/DE1007654T1/de active Pending
- 1998-02-18 CA CA002282497A patent/CA2282497C/en not_active Expired - Fee Related
- 1998-02-18 IL IL13143598A patent/IL131435A0/xx active IP Right Grant
- 1998-02-18 WO PCT/GB1998/000518 patent/WO1998037186A1/en active IP Right Grant
- 1998-02-18 US US09/331,808 patent/US7416847B1/en not_active Expired - Fee Related
- 1998-02-18 DE DE69830497T patent/DE69830497T2/de not_active Expired - Lifetime
- 1998-02-18 PT PT98905520T patent/PT1007654E/pt unknown
- 1998-02-18 AU AU61086/98A patent/AU744791B2/en not_active Ceased
-
1999
- 1999-08-17 IL IL131435A patent/IL131435A/en not_active IP Right Cessation
- 1999-08-17 NO NO19993953A patent/NO322653B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| PT1007654E (pt) | 2005-08-31 |
| EP1007654B1 (en) | 2005-06-08 |
| GB9703369D0 (en) | 1997-04-09 |
| IL131435A (en) | 2008-06-05 |
| JP2001512474A (ja) | 2001-08-21 |
| WO1998037186A1 (en) | 1998-08-27 |
| DE1007654T1 (de) | 2000-10-05 |
| NO993953L (no) | 1999-10-18 |
| ES2241117T3 (es) | 2005-10-16 |
| DE69830497D1 (de) | 2005-07-14 |
| CA2282497C (en) | 2007-04-24 |
| JP4644321B2 (ja) | 2011-03-02 |
| IL131435A0 (en) | 2001-01-28 |
| US7416847B1 (en) | 2008-08-26 |
| CA2282497A1 (en) | 1998-08-27 |
| AU744791B2 (en) | 2002-03-07 |
| DK1007654T3 (da) | 2005-09-19 |
| NO993953D0 (no) | 1999-08-17 |
| ATE297462T1 (de) | 2005-06-15 |
| EP1007654A1 (en) | 2000-06-14 |
| AU6108698A (en) | 1998-09-09 |
| DE69830497T2 (de) | 2006-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO322653B1 (no) | Fremgangsmate for femstilling av et in vitro peptid- eller proteinekspresjonsbibliotek, peptid- eller proteinekspresjonsbibliotek, fremgangsmate for a identifisere et malmolekyl, samt bifunksjonell molekylaer probe for anvendelse i en slik fremgangsmate. | |
| JP6236563B2 (ja) | 核酸の生成 | |
| JP5009481B2 (ja) | 定方向進化方法 | |
| DK2348124T3 (en) | Synthesis of a bifunctional complex | |
| US11118215B2 (en) | Method for obtaining structural information concerning an encoded molecule and method for selecting compounds | |
| AU2001286103A1 (en) | Directed evolution method | |
| NO332949B1 (no) | Fremgangsmate for fremstilling av et in vitro peptidekspresjonsbibliotek av DNA-bundne peptider | |
| JP2017060513A (ja) | 富化ライブラリーを作製する方法 | |
| US20030124537A1 (en) | Procaryotic libraries and uses | |
| JP2001520022A (ja) | 生物学的相互作用を調節する新規化合物についてのスクリーニング | |
| WO2003000856A2 (en) | In vitro protein interaction detection systems | |
| EP1442134B1 (en) | Method for producing and identifying soluble protein domains | |
| AU2010217551B2 (en) | Signal sequence-independent pIX phage display | |
| AU2002341204A1 (en) | Method for producing and identifying soluble protein domains | |
| JP2006211984A (ja) | エマルジョンを利用した核酸増幅方法、及び核酸増幅反応用キット | |
| JP2024522764A (ja) | 遺伝子編集のため、並びにプログラム可能な遺伝子活性化及び阻害のための微小ｃｒｉｓｐｒヌクレアーゼを含むシステム、方法及び組成物 | |
| Smiley et al. | Sequence-directed covalent protein-RNA linkages using engineered HUH-Tags | |
| Zeiler et al. | Improved approach to RNA and protein recognition for pathogen detection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |